Immutep Ltd

  • IPO date:
  • Sector: Healthcare
  • GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
  • Industry: Biotechnology
  • Company website

Company description

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Financial highlights

Market Capitalization$338.3823 million
P/E Ratio0
P/E Growth Ratio
Book Value0.087
Dividend Per Share0
Earnings Per Share-0.05
EBITDA-37,424.136
Profit Margin0
Operating Margin TTM-8.6276
Return on Assets TTM-0.2321
Return on Equity TTM-0.3941
Revenue TTM4,438.558

Income statement highlights

All numbers are in thousands

Date Total Revenue Cost of Revenue Gross Profit Total Operating Expenses
2000-06-30 42
2001-06-30 9 1,241
2002-06-30 407 90
2003-06-30 147 242
2004-06-30 352 394
2005-06-30 1,068 332
2006-06-30 3,877 215
2007-06-30 156 140
2008-06-30 58 143 1,934.552
2009-06-30 29 218 2,384.028
2010-06-30 523.734 523.734 8,392.452
2011-06-30 1,066 15,196.438
2012-06-30 1,520.019 14,501 1,520.019 22,654.783
2013-06-30 1,649 14,005 3,066.338 17,461.753
2014-06-30 2,020 11,931 2,426.755 14,449.713
2015-06-30 1,554.62 8,952.447 1,873.76 14,681.222
2016-06-30 175.052 7,059.528 -5,294.65 61,913.495
2017-06-30 4,221.1 7,525.744 -3,409.011 9,457.578
2018-06-30 2,630.484 9,989.83 -3,136.227 14,324.214
2019-06-30 139.782 16,591.201 139.782 19,102.197
2020-06-30 7,486.444 7,486.444 22,558.461
2021-06-30 418.17 19,656.079
2022-06-30 170.369 170.369 34,007.707
2023-06-30 1,130.72

Balance sheet highlights

All numbers are in thousands

Date Cash Total Assets Total Liabilities Short Term Debt Long Term Debt Common Stock
2000-06-30 687 2,095 219 7,819
2001-06-30 2,992 4,244 102 11,106
2002-06-30 3,715 5,926 466 15,312
2003-06-30 1,579 3,968 875 18,404
2004-06-30 2,785 5,768 641 25,345
2005-06-30 7,533 9,131 788 34,846
2006-06-30 3,211 7,360 1,043 37,142
2007-06-30 672 4,358 278 37,825
2008-06-30 1,109.259 2,821.25 187.817 39,745
2009-06-30 950.561 2,489.62 677.098 240.385 42,137
2010-06-30 15,640.607 19,011.184 2,223.67 700 65,309
2011-06-30 45,930.764 57,640.661 2,541.531 10,000 125,066
2012-06-30 17,004.763 41,612.671 4,454.8 21,045.423 127,051
2013-06-30 22,023.143 32,814.298 3,565.88 8,000 142,326.977
2014-06-30 14,200.042 25,377.955 2,785.635 9,000 149,014.372
2015-06-30 6,759.615 30,983.445 6,293.702 1,508.473 179,887.135
2016-06-30 20,879.548 42,554.067 7,236.554 0 5,027.17 194,530.932
2017-06-30 12,236.974 34,963.796 8,431.49 5,778.984 5,778.98 195,352.543
2018-06-30 23,475.521 46,998.783 13,476.856 6,645.832 6,645.83 213,232.719
2019-06-30 16,567.982 40,541.499 16,153.783 0 7,642.71 221,091.591
2020-06-30 26,322.047 46,597.252 13,297.907 129.412 8,789.11 242,990.507
2021-06-30 60,128.191 82,030.533 8,758.922 208.194 2,526.87 313,422.305
2022-06-30 79,995.129 102,169.55 8,092.184 173.377 2,112.12436 367,407.757
2023-06-30 119,829.51 147,448.99 10,979.6 0 835.45 446,272.2

Cash flow highlights

All numbers are in thousands

Date Net Income Total Cash Change in Cash Begin period cash End period cash Dividends
2000-06-30
2001-06-30
2002-06-30
2003-06-30
2004-06-30
2005-06-30
2006-06-30
2007-06-30 671.78
2008-06-30 -1,887.356 -1,554.336 426.479 671.78 1,098.259
2009-06-30 -2,946.356 -1,883.47 -158.698 1,098.259 939.561
2010-06-30 -12,158.848 -6,461.68 4,698.781 939.561 5,638.342
2011-06-30 -21,081.095 -9,755.703 40,280.21 5,638.342 45,918.552
2012-06-30 -19,940.96 -19,120.369 -28,926.836 45,918.552 16,991.716
2013-06-30 -15,225.671 -16,037.126 5,031.427 16,991.716 22,023.143
2014-06-30 -13,343.381 -14,227.161 -7,823.101 22,023.143 14,200.042
2015-06-30 -32,151.696 -7,786.982 -7,440.427 14,200.042 6,759.615
2016-06-30 -62,015.184 -11,309.691 14,119.933 6,759.615 20,879.548
2017-06-30 -9,367.206 -8,506.798 -8,642.574 20,879.548 12,236.974
2018-06-30 -12,746.02 -7,776.703 11,238.547 12,236.974 23,475.521
2019-06-30 -18,343.984 -15,286.398 -6,907.539 23,475.521 16,567.982
2020-06-30 -13,468.232 -10,839.339 9,754.065 16,567.982 26,322.047 0
2021-06-30 -29,902.624 -17,640.342 34,271.144 26,322.047 60,593.191
2022-06-30 -32,210.826 -30,229.752 19,401.938 60,593.191 79,995.129 0
2023-06-30 -35,883 43,423 79,995 123,418 0